Edmond de Rothschild appoints a new partner to life science VC arm

Siddiqi brings 13 years of venture capital investment experience in companies focused on innovation. He will be joining the life sciences team to select new investment opportunities and supporting portfolio companies of the recently raised €192m BioDiscovery 4 venture fund.

Siddiqi’s career spans medicine, investment banking and venture capital/growth equity. Prior to joining the Edmond de Rothschild Group, he was a partner at Phase4 Ventures. Before that, he was part of a small initial founding group of investment professionals who helped to build a global healthcare investment business for Nomura with several hundred million dollars of invested capital

Founded in 1953, Edmond de Rothschild Group has been chaired by Baron Benjamin de Rothschild since 1997. As at 30 June 2013, it had CHF163bn (€135.7bn) in assets under management.

BioDiscovery 4 took the total funds raised by the firm for investment in European life sciences businesses to €450m. The fund held a first closing on €125m in July 2012, and at the time the firm said it was seeking to raise €200m by the end of the year. The fund was backed by include the majority of EdRIP’s life science existing investor base, including the Edmond de Rothschild Group and La Banque Publique d’Investissement.Other investors include insurance companies, retirement funds, public pension funds and other institutional investors.